590 related articles for article (PubMed ID: 26956051)
1. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
2. Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs).
Pircher A; Fiegl M; Untergasser G; Heidegger I; Medinger M; Kern J; Hilbe W
Lung Cancer; 2013 Aug; 81(2):252-8. PubMed ID: 23664449
[TBL] [Abstract][Full Text] [Related]
3. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
Rodríguez Garzotto A; Díaz-García CV; Agudo-López A; Prieto García E; Ponce S; López-Martín JA; Paz-Ares L; Iglesias L; Agulló-Ortuño MT
Med Oncol; 2016 Oct; 33(10):105. PubMed ID: 27568331
[TBL] [Abstract][Full Text] [Related]
4. Resistance to angiogenesis inhibitors in renal cell carcinoma.
Tamaskar I; Dhillon J; Pili R
Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm.
Chu BF; Otterson GA
Clin Lung Cancer; 2016 Nov; 17(6):493-506. PubMed ID: 27381269
[TBL] [Abstract][Full Text] [Related]
6. Resistance to antiangiogenic therapies.
Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
[TBL] [Abstract][Full Text] [Related]
8. Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer.
Pompas-Veganzones N; Sandonis V; Perez-Lanzac A; Beltran M; Beardo P; Juárez A; Vazquez F; Cozar JM; Alvarez-Ossorio JL; Sanchez-Carbayo M
Tumour Biol; 2016 Oct; 37(10):14301-14310. PubMed ID: 27592258
[TBL] [Abstract][Full Text] [Related]
9. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
[TBL] [Abstract][Full Text] [Related]
10. [Are antiangiogenic antibodies universal for solid tumor?].
Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
[TBL] [Abstract][Full Text] [Related]
11. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapies in non-small-cell lung cancer.
Alshangiti A; Chandhoke G; Ellis PM
Curr Oncol; 2018 Jun; 25(Suppl 1):S45-S58. PubMed ID: 29910647
[TBL] [Abstract][Full Text] [Related]
13. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
14. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
15. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
16. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
18. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of AGGF1 is correlated with angiogenesis and poor prognosis of hepatocellular carcinoma.
Wang W; Li GY; Zhu JY; Huang DB; Zhou HC; Zhong W; Ji CS
Med Oncol; 2015 Apr; 32(4):131. PubMed ID: 25796501
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
Deplanque G; Madhusudan S; Jones PH; Wellmann S; Christodoulos K; Talbot DC; Ganesan TS; Blann A; Harris AL
Br J Cancer; 2004 Nov; 91(9):1645-50. PubMed ID: 15354209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
